Introduction
With more than 50 000 transplants per year, the cornea is the most commonly transplanted solid tissue. [1] [2] [3] Immunologic rejection is still the leading cause of corneal allograft failure, especially in high-risk recipients with a history of previous graft rejection, inflammation or neovascularization. These transplant recipients may in fact represent the majority of patients seen in several clinical centres. To avoid rejection, topical immunosuppressive therapy is routinely performed. However, the results are not satisfying despite the cornea's location in an 'immune-privileged' environment. But for most of these patients the risk of systemic immunosuppression accompanied with severe side effects may not be justified as they do not suffer from a life-threatening disease. Therefore, less toxic treatment protocols are desirable.
The precise mechanisms by which corneal grafts are rejected remain a subject of investigation, but the central role of T lymphocytes is unquestioned. A number of studies indicate that rejection of corneal allografts is mediated predominantly by a Th1-response identified on the distinct cytokine profile detected within rejected corneal grafts as well as in aqueous humor of experimental animals undergoing transplant failure. [4] [5] [6] [7] Interleukin-10 (IL-10), originally described as cytokine synthesis inhibitory factor 8 is a potent immunomodulatory cytokine that interacts with antigen presenting cells. In addition, IL-10 inhibits production of monokines such as IL-1, IL-6, IL-8 and tumour necrosis factor (TNF)-a. [9] [10] [11] [12] In contrast to cellular IL-10, the Epstein-Barr virus encoded IL-10 homologue (vIL-10) only shows these immunosuppressive properties but not stimulatory effects on natural killer cells and cytotoxic T lymphocytes (CTL). 13, 14 Gene transfer and gene therapy leading to IL-10 expression in allogeneic transplants may therefore be a promising therapy to impair effective antigen presentation, reduce graft immunogenicity and inhibit inflammation. Indeed, it has been shown that gene transfer of IL-10 led to prolonged graft survival in different transplant models including the cornea, 13, [15] [16] [17] [18] however, in the latter one, the mechanism of graft prolongation is not clear.
Here, we report on the modulation of corneal transplants by ex vivo vIL-10 gene transfer using either liposomes or adenoviral particles before transplantation in a high-responder major histocompatibility complex (MHC) class I/II mismatched rat model. We show that neither ex vivo liposomal-nor adenovirus-mediated gene transfer in cultured corneas resulted in prolongation of graft survival. In contrast, systemic expression of vIL-10 in transplant recipients significantly prolonged allograft survival. Moreover, we demonstrate that modulation of the cytokine profile in the draining lymph nodes rather than in the graft itself seems to be required for the success of the therapy.
Results
Local liposome-mediated vIL-10 gene transfer into cultured corneas resulted in considerable protein expression but did not lead to prolongation of corneal allograft survival
Corneas from WF rats (n ¼ 4) were transfected with different concentrations of vIL-10 plasmid (2.5, 5, 10, 20 mg, respectively) and cultured for up to 8 days. On days 1, 2, 4, 6 and 8, supernatants were collected and analysed for vIL-10 protein expression ( Figure 1a ). We could show that transfection of either 2.5 or 5 mg plasmid DNA resulted in considerable vIL-10 secretion peaking on day 8 after gene transfer. Based on the results from these experiments a concentration of 2.5 mg plasmid was chosen for all subsequent experiments.
To investigate the protective effect of local liposomemediated vIL-10 gene therapy on corneal allograft survival, corneas were harvested from organ donors, transfected ex vivo with liposome-mediated vIL-10 plasmid (2.5 mg) or the reporter gene Escherichia coli b-galactosidase (b-Gal) (2.5 mg) as vector control and transplanted in MHC class I/II disparate recipients. During a period of 5 days after transplantation, the grafts suffered from slight stromal oedema but then recovered and remained clear until rejection. Transplantation of either untreated (control) or vector-treated (b-Gal) corneal grafts resulted in a rejection rate of 100%. The survival data are shown in Figure 1b . No difference in allograft survival between the control (median survival times (MST) 10.5670.34 days, n ¼ 9), the vector control group (MST 10.6770.67 days, n ¼ 6, P ¼ 0.6498) and the local liposome-mediated vIL-10 gene transfer group could be observed (MST 12.070.38 days, n ¼ 8, P ¼ 0.1616 compared with the vector control).
Local AdvIL-10 gene therapy failed to prolong corneal allograft survival
Next we analysed whether improved corneal allograft survival could be achieved by local Ad-mediated vIL-10 gene transfer as we have shown previously that this approach leads to enhanced vIL-10 expression. 19 Donor corneas were transduced either with the AdvIL-10 (1 Â 10 8 PFU (plaque forming units)) or Adb-Gal (1.0 Â 10 8 PFU) construct as vector control and transplanted in high-responder MHC class I/II disparate recipients. The survival data are shown in Figure 2a . Interestingly, a difference in allograft survival between the control (MST 10.5670.34 days, n ¼ 9) and the vector control Adb-Gal group (MST 12.070.73 days, n ¼ 6) could be observed (P ¼ 0.0386). However, AdvIL-10 gene transfer did not lead to prolonged allograft survival compared with the vector control (MST 12.070.38 days, n ¼ 6, P ¼ 0.4719). 
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To investigate the mechanisms of immunomodulation of local AdvIL-10 gene therapy in more detail, we analysed the cytokine expression profile in both allografts and the draining lymph nodes of recipients at day 9 after transplantation by quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR) (n ¼ 4). Day 9 after transplantation was selected based on the assumption that rejection is already in process in control animals but inhibited in grafts/animals receiving therapy. We found only a mild reduced infiltration of inflammatory cells in corneal grafts (CD3 and CD25, change o5 fold) (Figure 2b ). However, no significant changes in the messenger RNA (mRNA) expression profile in draining lymph nodes (cervical lymph nodes for corneal immunity) could be observed (Figure 2c ).
Systemic AdvIL-10 gene therapy prolonged corneal allograft survival and modulated the immune response in the draining lymph nodes
In the next series of experiments we wanted to analyse if systemic AdvIL-10 gene therapy is able to modulate the rejection kinetics of corneal graft survival. On the day before transplantation (day-1), either AdvIL-10 (1.0 Â 10 9 PFU) or Adb-Gal (1.0 Â 10 9 PFU) as vector control was administered intraperitoneally (i.p.). The next day, corneal transplantation was performed as described before. The survival data are shown in Figure  3a . No difference in allograft survival between the control (MST 10.5670.34 days, n ¼ 9) and the vector control Adb-Gal group (MST 9.8370.31 days, n ¼ 6) could be observed (P ¼ 0.1356). However, in animals receiving systemic AdvIL-10 gene transfer allograft survival was significantly prolonged compared with controls (MST 14.671.01 days, n ¼ 5, P ¼ 0.0042) including one out of five grafts surviving indefinitely ( Figure 3a) . Moreover, IL-10 protein could be detected in animals receiving i.p. AdvIL-10 on day 7 after transplantation (day 8 after Adinjection) (Figure 3b ). Interestingly, in contrast to the therapeutic effect of AdvIL-10 (1.0 Â 10 9 PFU), administration of high-dose AdvIL-10 (1.0 Â 10 10 PFU) did not lead to prolongation of corneal allograft survival compared with the controls (MST 10.8670.26 days, n ¼ 7, P ¼ 0.6671). In addition, IL-10 protein could not be detected in these animals ( Figure 3b) .
To investigate the immunomodulatory mechanisms of systemic AdvIL-10 gene therapy in more detail, two additional groups (no treatment and systemic AdvIL-10 treatment, four animals in each group) were employed, and the mRNA expression profile in both allografts and the draining lymph nodes was analysed by qRT-PCR on day 9 after transplantation (n ¼ 8). No major differences between the two groups could be found in corneal allograft samples (Figure 3c ). In the draining lymph nodes, however, the mRNA expression of rat IL-10 was highly increased, suggesting that systemic vIL-10 gene expression is able to modulate the immune response in the draining lymph nodes (Figure 3d ).
Anti-adenovirus immunity limited therapeutic protein expression and the effect of adenovirus-mediated gene therapy
To investigate the striking differences between systemic AdvIL-10 gene therapy groups (1.0 Â 10 9 PFU ¼ prolongation, 1.0 Â 10 10 PFU ¼ no prolongation) in more detail, we analysed whether anti-adenovirus immunity may be involved. Subsequently, sera from animals receiving systemic Ad-therapy were collected at day 7 after transplantation and analysed for the detection of antiadenovirus antibodies (Figure 4 ). Following systemic Adb-Gal gene transfer high levels of anti-adenovirus antibodies as measured by enzyme-linked immunosorbent assay (ELISA) could be observed (OD43.0). In the sera of animals receiving systemic AdvIL-10 gene transfer (1.0 Â 10 9 PFU), anti-adenovirus antibodies could be detected, however, levels varied but were overall reduced compared with vector-treated controls. Interestingly, two recipients were without detectable levels of anti-adenovirus antibodies. However, systemic 
Discussion
We have investigated the influence of IL-10 gene therapy on corneal allograft survival in a MHC class I/II mismatched rat model. Genetic modification of corneal tissue before transplantation is of particular interest asunlike other organs -donor corneas can be stored ex vivo for prolonged periods of time without significant loss of function. Moreover, systemic treatment of the transplant recipient would not be required which would be a major advantage for this therapy. Local gene transfer of immunomodulatory cytokines, for example, IL-10 has been shown to prevent graft rejection in various transplant models including the cornea. 13, [15] [16] [17] [18] However, the results presented here indicate that local expression of IL-10 is not sufficient to prevent corneal graft rejection in a full mismatched rat transplant model.
Liposome-mediated gene transfer in corneal endothelial cells has been suggested as an interesting technology without inducing immune responses against the transfected cells. 20 However, the efficiency of gene transferparticularly in solid tissues -seems to be low compared with viral vectors. 19 Nevertheless, we have obtained significant amounts of vIL-10 in the supernatants of cultured corneas after liposomal gene transfer (Figure 1a) beginning from day 4 until the end of the observation period. However, transplantation of corneas, which have been transfected with vIL-10 did not lead to prolonged survival (Figure 1b) . One possible explanation for the failure of the liposome-mediated gene transfer could be that the levels of IL-10 protein secreted by transfected corneas still might be too low for effective immunomodulation. To investigate this we used an adenoviral gene transfer system for the ex vivo transduction of corneas which leads to high levels of therapeutic gene expression. 19 However, similar to the results obtained after liposomal gene transfer local IL-10 gene transfer mediated by AdvIL-10 did not lead to prolonged allograft survival (Figure 2a) . Recently, it has been described that Ad-mediated gene transfer of ovine IL-10 prolongs graft survival in a sheep transplant model. 18 However, in our rat MHC class I/II mismatched transplant model neither liposome-mediated nor Ad-mediated IL-10 gene transfer resulted in significant prolongation of graft survival. In order to address these controversial results in more detail we analysed the immunomodulatory effects of IL-10 gene transfer on the mRNA expression profile in corneal allografts and in draining lymph nodes. It is well known that gene transfer using adenoviral vectors induces both humoral and cellular immunity which may limit the success of Ad-mediated gene therapy. [21] [22] [23] However, the induction of an immune response against the virus and/ or transduced cells is not clear in an 'immune-privileged' environment such as the eye. We found that local AdvIL-10 gene transfer did not lead to an increased infiltration of inflammatory cells (Figure 2b) . Similar results on corneal allograft survival have been obtained using an Ad-vector expressing IL-4, another anti-inflammatory cytokine with potential to induce T-helper 2 cells. 24 Interestingly, local IL-10 gene transfer did not modulate inflammatory cells in the draining lymph nodes where cornea-related antigen presentation and T-cell activation might take place (Figure 2c ). In summary, prevention of corneal allograft rejection by intra-graft gene transfer seems to be less successful than it has been described for other organs. Whether this is related to different rejection kinetics of corneal grafts or to differences in therapeutic gene expression is not clear. We conclude that ex vivo modulation of cultured corneas with anti-inflammatory cytokines either by liposomal or by adenoviral gene transfer is not a successful approach to prevent corneal graft rejection in a MHC class I/II disparate transplant model. Interestingly, the majority of genetic modifications to prevent corneal graft rejection require a systemic expression of the therapeutic protein 25, 26 although few reports on successful prevention of graft rejection using local gene transfer have been published. 18, 27, 28 Next we asked the question if prevention of corneal graft rejection requires the expression of the therapeutic gene and/or the modulation of cells in compartments where antigen presentation and lymphocyte activation takes place (e.g. lymph node and spleen). To prove this hypothesis vIL-10 was overexpressed by i.p. injection of the recombinant Ad in corneal transplant recipients. We could show that in contrast to local gene therapy systemic expression of vIL-10 led to prolonged graft survival (Figure 3a) . Whereas it seems that systemic vIL-10 gene therapy does not influence graft infiltration the mRNA expression profile in draining lymph nodes was profoundly altered (Figure 3c and d) . AdvIL-10 gene therapy led to increased levels of IL-10 in the lymph nodes, probably mediated by an increased number of CD3+ cells in the lymph nodes. Our results indicate that attempts to manipulate the immune system, for example, using anti-inflammatory cytokines to prevent corneal graft rejection immunomodulation in the lymph nodes is required but it is not or less important in the graft itself.
It is widely accepted that systemic injection of adenoviral vectors led to humoral and cellular immune responses against the vector and the transduced cells influencing the success of the therapy. [21] [22] [23] Although corneal allograft survival was significantly prolonged, anti-adenovirus immunity was induced after systemic injection of AdvIL-10 as measured by the detection of antibodies against the virus capsid. Interestingly, levels of anti-adenovirus antibodies were reduced compared with control vector-treated animals (Figure 4 ). This might Ad -Gal AdvIL-10 optical density (OD) Figure 4 Detection of anti-adenovirus immunity. Sera from animals receiving systemic Ad-therapy were collected at day 7 after transplantation and analysed for the presence of antiadenovirus antibodies by specific IgG ELISA. Each column represents the serum of individual animals.
vIL-10 gene therapy in corneal transplantation N Gong et al indicate that systemic IL-10 expression also influences the generation of antibodies either by directly affecting B cells or by influencing T-cell help for B cells. However, there seems to be a subtle balance between the expression of the cytokine and the modulation of the immune response. When AdvIL-10 was injected at high dose (1.0 Â 10 10 PFU) no prolongation of corneal graft survival was observed (Figure 3a) . In addition, no IL-10 protein and very high levels of anti-adenovirus anti-bodies were found. This indicates that high doses of Ad-vectors may induce a strong immune response which is able to overcome the immunomodulatory effect of IL-10 and which would be a problem for the translation of this approach into the clinics. Interestingly, the application of an Ad-vector expressing a CTLA4Ig fusion protein which blocks co-stimulatory signals in T cells is able to effectively prevent strong anti-adenoviral immune responses even after the application of high-dose adenoviral vectors. 26 In summary, we have shown that local IL-10 gene therapy is not able to prevent corneal graft rejection. In contrast, systemic expression of IL-10 effectively prolongs corneal graft survival. Moreover, immunomodulation in the draining lymph nodes rather than in the graft itself seems to be a prerequisite for an efficient therapy to prolong allogeneic graft survival.
Materials and methods

Animals
Inbred female rats of Wistar-Furth (WF, RT.1 u ) and Lewis (LEW, RT.1A 1 ) strains weighing 200-250 g were obtained from Charles River (Kisslegg, Germany). Lewis rats served as recipients of WF grafts. All animals were housed in wire-bottomed cages with controlled light/ dark cycles, fed with a standard laboratory diet and given free access to tap water. Animals were handled in accordance with the National Institute of Health 'Guide for the Care and Use of Laboratory Animals' and German guidelines on the use of animals in research (Berliner Senatsverwaltung).
Corneal transplantation and definition of graft rejection
Orthotopic corneal transplantation was performed as reported previously. 26, 29 Briefly, all animals were anaesthetized by intramuscular injection of a mixture of ketamine (90 mg/kg, Ketavet; Pharmacia GmbH, Erlangen, Germany) and xylazine (7.5 mg/kg, Rompun 2%; Bayer Vital GmbH, Leverkusen, Germany) diluted in saline during the surgical procedure. Before surgery 1% atropine sulphate drops (Ciba Vision, Wefling, Germany) were topically applied to dilate the pupil. The recipient and donor right cornea were trephined with a 3.0 or 3.5 mm trephine, respectively, and excised using Vannas scissors. The donor graft was sutured into the recipient bed using a running suture (10-0 Mersilene; Ethicon, Hannover, Germany). The suture was not removed. After transplantation, antibiotic ointment (Ofloxacin, Floxal, Mann Pharma, Berlin, Germany) was applied immediately to the eye. Animals with surgical complications such as intraocular haemorrhage or cataract were excluded. Corneal transparency as an indicator of corneal endothelial function and of graft endothelial injury was evaluated daily. Corneal opacity was graded as follows: 0, completely transparent cornea; 1, slight corneal opacity, but iris vessels easily visible; 2, moderate corneal opacity, iris vessels still visible; 3, moderate corneal opacity, only pupil margin visible; 4, complete corneal opacity, pupil not visible. Corneas with opacity grades of 3 or 4 were diagnosed as rejected. [29] [30] [31] Ex vivo transfection of corneal transplants with liposome-mediated vIL-10 and local gene therapy 100 ml Dulbecco's modified Eagle's medium (DMEM), supplemented with Glutamine, antibiotics (P/S) and 2 ml fetal calf serum (FCS) were used to prepare corneal culture medium which was stored at 41C until use. 250 ml Opti-MEM (Invitrogen, Karlsruhe, Germany), 5 ml Lipofectamin (Invitrogen), different concentrations of vIL-10 plasmid (pcDSRa-BCRF1, kindly provided by Dr René de Waal Malefyt, DNAX, Palo Alto, CA, USA), or control b-Gal plasmid and 10 ml transferrin (Sigma-Aldrich Chemie GmbH, Schnelldorf, Germany) were mixed as liposome/plasmid mixture. The mixture was kept at room temperature for 30 min. Donor corneas were excised and cultured in 24-well plates. After washing twice with 500 ml Opti-MEM, 250 ml liposome/plasmid mixture was added into each well and incubated at 371C and 5% CO 2 for 3 h. After removal of the mixture followed by three times washing with medium corneal samples were kept in 1 ml culture medium at 371C. To evaluate the efficiency of ex vivo transduction of corneal transplants, corneas from WF rats (n ¼ 4) were transfected with liposome-mediated vIL-10 (vIL-10 plasmid: 2.5, 5, 10 and 20 mg, respectively) in 1 ml corneal culture medium. The medium was changed every day and vIL-10 protein levels were analysed at different time points (days 1, 2, 4, 6 and 8) by specific ELISA (CoulterImmunotech, Hamburg, Germany).
For ex vivo liposome-mediated vIL-10 gene therapy experiments, a plasmid concentration of 2.5 mg vIL-10 was chosen and after 3 h of incubation to allow early gene expression corneal samples were implanted into recipients.
Generation of recombinant adenovirus vectors
The generation of replication-defective recombinant Adenovirus (Ad) type 5 expressing the therapeutic genes vIL-10 and the reporter gene b-Gal has been described previously. 19, 32, 33 Ex vivo transduction of corneal transplants with AdvIL-10 and local and systemic administration of AdvIL-10 into recipients
To evaluate the efficiency of ex vivo transduction of corneal transplants, corneas from WF rats (n ¼ 3) were transduced with AdvIL-10 (1.0 Â 10 8 PFU) for 3 h at 371C in 500 ml of culture medium (DMEM). After careful washing, corneas were further cultured for 48 h (DMEM, 2% FCS) in order to detect IL-10 protein in the supernatant.
For transplant experiments donor corneas were excised and cultured in 24-well plates incubated at 371C and 5% CO 2 for 3 h with 500 ml DMEM containing 1.0 Â 10 8 PFU of AdvIL-10 (1 Â 10 8 PFU) or Adb-Gal (1 Â 10 8 PFU). After 3 h of transduction, supernatants were removed, corneas were carefully washed three times and incubated for additional 3 h in 500 ml DMEM vIL-10 gene therapy in corneal transplantation N Gong et al at 371C before transplantation for local gene therapy groups. For systemic administration of AdvIL-10, 1.0 Â 10 9 PFU or 1.0 Â 10 10 PFU (high-dose) in 500 ml of phosphate-buffered saline were injected i.p. into transplant recipients at the day before transplantation.
Detection of IL-10 in culture supernatants or in sera Culture supernatants or sera from animals receiving systemic gene therapy were analysed for vIL-10 content by specific ELISA according to the manufacturer's instructions (Coulter-Immunotech, Hamburg, Germany, detection limit is 16 pg/ml).
Detection of anti-adenovirus antibodies by specific ELISA
Serum samples from different gene therapy groups were analysed for the presence of immunoglobulin (Ig)G anti-adenovirus antibodies by specific antigen ELISA according to the manufacturer's instructions (Virotech, Rü sselsheim, Germany). Sera were diluted 1:100 and an anti-rat IgG-conjugate (horseradish peroxidase) was used for the specific detection of anti-adenovirus antibodies. Sera from naïve animals or from animals treated systemically with recombinant adenovirus expressing other transgenes were used as negative or positive control, respectively.
qRT-PCR for the analysis of mRNA expression profiles in corneal samples mRNA was isolated from single corneas according to standard protocols. The following parameters were investigated for its mRNA expression profile in corneal allograft sample by qRT-PCR: CD3, CD25, IFN-g, TNF-a and IL-10. A detailed description of the technique used is given elsewhere. 26 All samples were normalized regarding their b-actin content. All reactions were performed on the ABI Prism 7700 Sequence Detection System (Perkin Elmer Applied Biosystems, Weiterstadt, Germany).
Statistical analysis
Graft survival was analysed using the Kaplan-Meier survival method. The log-rank test was used to compare graft survival times as Mantel-Haenszel survival analysis. As some data were not normally distributed and equality of variance could not be assumed, nonparametric statistical tests (Mann-Whitney U and Kruskal-Wallis) were used to compare MST. Po0.05 was defined as statistically significant.
